The dichotomy of placenta-derived cells in cancer growth

Ornella Parolini, Antonietta R. Silini, Sara Cancelli, Patrizia Bonassi Signoroni, Anna Cargnoni, Marta Magatti

Research output: Contribution to journalArticle

7 Citations (Scopus)


Placenta-derived mesenchymal stromal cells (MSC) have often been considered to linger behind their equivalents from other tissues, such as MSC from bone marrow, in many aspects including their therapeutic potential in regenerative medicine. Nowadays however, it is clear that certain aspects make placental MSC attractive as a cellular therapy, such as their lack of ethical concerns and ease of isolation from human term placenta, a material long regarded as biological waste. Moreover, placental MSC virtually lack expression of human leukocyte antigens and co-stimulatory molecules, making them very attractive for transplantation in allogeneic settings.In the context of cancer, cell therapy remains an area of intense investigation whereby MSC have been shown to play opposing roles, and placental MSC are no exception. In this review, we will discuss dichotomy of placental MSC that underscores the challenges in understanding their therapeutic potential in oncology.
Original languageEnglish
Pages (from-to)154-162
Number of pages9
Publication statusPublished - 2017


  • Amniotic membrane
  • Cancer
  • Chorion
  • Decidua
  • Developmental Biology
  • Mesenchymal stromal cells
  • Obstetrics and Gynecology
  • Placenta
  • Reproductive Medicine
  • Umbilical cord


Dive into the research topics of 'The dichotomy of placenta-derived cells in cancer growth'. Together they form a unique fingerprint.

Cite this